Reader reproducibility high with 18F-rhPSMA-7.3 image interpretation in prostate cancer
June 15th 2022“These findings from the SPOTLIGHT study showed high inter-reader and intra-reader agreement for interpretation of 18F-rhPSMA-7.3 PET/CT scans in the setting of biochemical recurrence,” said Phillip Kuo, MD, PhD.
Novel PET imaging agent 18F-rhPSMA-7.3 increases upstaging in recurrent prostate cancer
May 14th 2022Compared with baseline conventional imaging, PET imaging with 18F-rhPSMA-7.3 frequently led to post-scan disease upstaging in men with prostate cancer recurrence, according to the latest data from the phase 3 SPOTLIGHT trial.